PRTC News and Press, PureTech Health plc From 10/05/21

Sonde extends use of its voice-based health detection and monitoring platform beyond respiratory illness to cognitive and mental health conditions PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stag...

Shionogi successfully completes first-ever clinical study of Akili’s video game-based cognitive treatment outside of the U.S.; plans to advance technology to the next step Data show Akili’s digital treatment was well-received and improved inattention in children ...

Dysfunction of the mesenteric lymphatics and leakage of pro-inflammatory lymph fluids promoted the accumulation of visceral adipose tissue and insulin resistance in a preclinical model Treatment with a lymph-targeted COX-2 inhibitor using PureTech’s Glyph TM technol...

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced that G...

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company, is pleased to note that its Founded Entity, Vor Biopharma (Nasdaq: VOR) (“Vor”) announced that the U.S. Food and Drug Admi...

Strong capital base and cash runway expected into the first quarter of 2025, with PureTech level cash and cash equivalents of $409.7 million 1 and consolidated cash and cash equivalents of $439.8 million 2 as of June 30, 2021 Continued advancement of PureTech’s ...

LYT-100 was well-tolerated when given twice-daily over multiple ascending doses with no maximum tolerated dose observed Results demonstrated dose-proportional PK profile and a modest food effect LYT-100 is currently being evaluated in two Phase 2 trials in patients wit...

Akili to license TALi’s technology for use in the U.S. as part of the agreement PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company today announced that its Founded Entit...

Industry veteran and board-certified physician to oversee advancement of PureTech’s clinical-stage Wholly Owned Pipeline PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics compa...

Imbrium Therapeutics has paid PureTech $6.5 million and PureTech is eligible to receive up to $53 million in additional development milestone payments for this program in addition to royalties on product sales Imbrium is responsible for all future development activities and fu...